Literature DB >> 15133860

Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Zhong-Ping Gu1, Yun-Jie Wang, Yu Wu, Jin-Ge Li, Nong-An Chen.   

Abstract

AIM: To investigate the designation, synthesis and biological activity of against vascular endothelial growth factor165 (VEGF165) ribozyme.
METHODS: The ribozyme against VEGF165 was designed with computer. The transcriptional vector was constructed which included the anti-VEGF165 ribozyme and 5', 3' self-splicing ribozymes. The hammerhead ribozyme and substrate VEGF165 mRNA were synthesized through transcription in vitro. The cleavage activity of the ribozyme on target RNA was observed in a cell-free system.
RESULTS: The anti-VEGF165 ribozyme was released properly from the transcription of pGEMRz212 cleaved by 5' and 3' self-splicing ribozymes which retained its catalytic activity, and the cleavage efficiency of ribozyme reached 90.7%.
CONCLUSION: The anti-VEGF165 ribozyme designed with computer can cleave VEGF165 mRNA effectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133860      PMCID: PMC4656291          DOI: 10.3748/wjg.v10.i10.1495

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

Review 1.  Hammerhead ribozymes: biochemical and chemical considerations.

Authors:  J Goodchild
Journal:  Curr Opin Mol Ther       Date:  2000-06

Review 2.  Angiogenesis and the unique nature of tumor matrix.

Authors:  Vincenzo Chiarug; Marco Ruggiero; Lucia Magnelli
Journal:  Mol Biotechnol       Date:  2002-05       Impact factor: 2.695

3.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Authors:  Dorina Belotti; Paola Paganoni; Luigi Manenti; Angela Garofalo; Sergio Marchini; Giulia Taraboletti; Raffaella Giavazzi
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

4.  Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer.

Authors:  Qingchang Li; Xin Dong; Wei Gu; Xueshan Qiu; Enhua Wang
Journal:  Chin Med J (Engl)       Date:  2003-05       Impact factor: 2.628

5.  Effects of anti-HPV16E6-ribozyme on phenotype and gene expression of a cervical cancer cell line.

Authors:  Yanfang Zheng; Jiren Zhang; Lianghu Qu
Journal:  Chin Med J (Engl)       Date:  2002-10       Impact factor: 2.628

Review 6.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

7.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

8.  Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.

Authors:  Philippe O Van Trappen; Dawn Steele; David G Lowe; Suhail Baithun; Nigel Beasley; Wilko Thiele; Herbert Weich; Jaya Krishnan; John H Shepherd; Michael S Pepper; David G Jackson; Jonathan P Sleeman; Ian J Jacobs
Journal:  J Pathol       Date:  2003-12       Impact factor: 7.996

9.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Authors:  Mercedes Fernandez; Francesco Vizzutti; Juan Carlos Garcia-Pagan; Juan Rodes; Jaime Bosch
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  1 in total

1.  Treatment of hemangioma by transfection of antisense VEGF gene.

Authors:  Shengguo Shan; Guang Shan; Duanlian Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.